These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 20959606)

  • 1. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
    Lannutti BJ; Meadows SA; Herman SE; Kashishian A; Steiner B; Johnson AJ; Byrd JC; Tyner JW; Loriaux MM; Deininger M; Druker BJ; Puri KD; Ulrich RG; Giese NA
    Blood; 2011 Jan; 117(2):591-4. PubMed ID: 20959606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
    Ikeda H; Hideshima T; Fulciniti M; Perrone G; Miura N; Yasui H; Okawa Y; Kiziltepe T; Santo L; Vallet S; Cristea D; Calabrese E; Gorgun G; Raje NS; Richardson P; Munshi NC; Lannutti BJ; Puri KD; Giese NA; Anderson KC
    Blood; 2010 Sep; 116(9):1460-8. PubMed ID: 20505158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
    Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ
    Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific inhibition of PI3K p110δ inhibits CSF-1-induced macrophage spreading and invasive capacity.
    Mouchemore KA; Sampaio NG; Murrey MW; Stanley ER; Lannutti BJ; Pixley FJ
    FEBS J; 2013 Nov; 280(21):5228-36. PubMed ID: 23648053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
    Bodo J; Zhao X; Sharma A; Hill BT; Portell CA; Lannutti BJ; Almasan A; Hsi ED
    Br J Haematol; 2013 Oct; 163(1):72-80. PubMed ID: 23889282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
    Alfaro J; Pérez de Arce F; Belmar S; Fuentealba G; Avila P; Ureta G; Flores C; Acuña C; Delgado L; Gaete D; Pujala B; Barde A; Nayak AK; Upendra TVR; Patel D; Chauhan S; Sharma VK; Kanno S; Almirez RG; Hung DT; Chakravarty S; Rai R; Bernales S; Quinn KP; Pham SM; McCullagh E
    J Pharmacol Exp Ther; 2017 May; 361(2):312-321. PubMed ID: 28298527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
    Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
    Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
    Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
    Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
    Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
    Castillo JJ; Furman M; Winer ES
    Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CAL-101,a novel agent of targeted therapy in hematological malignancies].
    Li CJ; Zhang Q; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):530-3. PubMed ID: 24763037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.
    Herman SE; Johnson AJ
    Clin Cancer Res; 2012 Aug; 18(15):4013-8. PubMed ID: 22711705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
    Herman SE; Lapalombella R; Gordon AL; Ramanunni A; Blum KA; Jones J; Zhang X; Lannutti BJ; Puri KD; Muthusamy N; Byrd JC; Johnson AJ
    Blood; 2011 Apr; 117(16):4323-7. PubMed ID: 21378270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
    Kim JH; Kim WS; Park C
    BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
    Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
    Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.
    Meadows SA; Vega F; Kashishian A; Johnson D; Diehl V; Miller LL; Younes A; Lannutti BJ
    Blood; 2012 Feb; 119(8):1897-900. PubMed ID: 22210877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
    Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
    Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
    Fruman DA; Rommel C
    Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.